Method for sterilizing pharmaceutical preparation and package
By using light blocking packaging and specific resin containers in AFDX0250 aqueous pharmaceutical compositions and filter sterilization, the hydrolysis and photodecomposition problems of AFDX0250 are solved, improving its stability and ensuring long-term preservation and safety of pharmaceutical preparations sex.
Patent Information
- Application Number
- CN202380030713.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-29
- Publication Date
- 2024-11-12
AI Technical Summary
AFDX0250 is easily hydrolyzed and photodecomposed in aqueous pharmaceutical compositions, resulting in stability problems. The prior art is difficult to effectively inhibit the generation of decomposition products, affecting the effectiveness and safety of the formulation.
AFDX0250 or its salt is stored in a light package with a wavelength of 210 to 380 nm, and a container is made of polyethylene, polypropylene or polyethylene terephthalate resin, and filtration and sterilization are combined with a filter to prevent Hydrolysis and photodecomposition.
The thermal stability and light stability of AFDX0250 in aqueous pharmaceutical compositions are significantly improved, ensuring the long-term storage stability and safety of the preparation, and avoiding the conversion of non-aqueous preparations.
Smart Images

Figure CN118946362A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to pharmaceutical preparations. Background Art
[0002] In order to develop a compound useful as an active ingredient of a medicine into a pharmaceutical product, it is necessary to satisfy various requirements, not only the effectiveness and safety of the pharmaceutical product, but also the stability of the compound in the pharmaceutical composition, the stability of the pharmaceutical composition, and the guarantee of the preservative effect. Among them, it is extremely important to ensure the stability of the compound in the pharmaceutical composition in order to stably exert the effect of the medicine.
[0003] Compounds useful as active ingredients of medicines have the following situation: even if they are stable in a solid state, they become unstable in a state of a pharmaceutical composition such as an aqueous solution, resulting in problems such as the generation of decomposition products or an increase in the amount of decomposition products. For example, sometimes the compound reacts with the moisture contained in the pharmaceutical additives and the like and decomposes, and the compound becomes unstable in the pharmaceutical composition. In addition, various physical factors such as pH, heat, moisture, and light sometimes affect the stability of the pharmaceutical composition. Therefore, it is important that the pharmaceutical composition is also stable relative to the above-mentioned various factors.
[0004] On the other hand, there are many cases where stability problems of compounds are not discovered until after the actual production of pharmaceutical compositions. Therefore, for the stabilization of compounds, generally, no general method is established, but a stabilization method suitable for the compound is found.
[0005] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-Ketone (hereinafter, sometimes referred to as "AFDX0250") is (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-Keto has the structure shown below and is useful for the treatment of eye diseases such as glaucoma, ocular hypertension and myopia (Patent Documents 1 and 2).
[0006] [Chemical formula 1]
[0007]
[0008] However, there has been no report on the stability of AFDX0250 or its salt in aqueous pharmaceutical compositions.
[0009] Prior art literature
[0010] Patent Literature
[0011] Patent Document 1: International Publication No. 93 / 18772
[0012] Patent Document 2: International Publication No. 2022 / 030489 Summary of the invention
[0013] Problems to be solved by the invention
[0014] The inventors of the present application discovered during the development stage of an aqueous pharmaceutical composition containing AFDX0250 or a salt thereof that when AFDX0250 is dissolved to prepare an aqueous pharmaceutical composition, AFDX0250 is easily hydrolyzed and 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine is easily precipitated as a hydrolyzate of AFDX0250. -6-ketone. It was further found that AFDX0250 or its salt is easily decomposed under light irradiation. Although the generation of decomposition products can be sufficiently suppressed in the previous preparations, further suppressing such decomposition products can improve the quality of the preparations compared with the previous preparations, and further improve the effectiveness and safety, which is very meaningful for the development of pharmaceutical preparations.
[0015] Therefore, an object of the present invention is to provide a pharmaceutical preparation having improved stability (for example, thermal stability and photostability) of AFDX0250 or a salt thereof in an aqueous pharmaceutical composition.
[0016] Means for solving problems
[0017] The inventors of the present application have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that by placing an aqueous pharmaceutical composition containing AFDX0250 or a salt thereof in a package that blocks light of wavelengths of 210 to 380 nm (particularly 216 nm to 310 nm and 372 nm), decomposition of AFDX0250 or a salt thereof due to light exposure can be suppressed, and formulation stability can be ensured. In addition, the inventors of the present application have found that by placing an aqueous pharmaceutical composition containing AFDX0250 or a salt thereof in a plastic container (particularly a polyethylene (PE) resin container, a polypropylene (PP) resin container, and a polyethylene terephthalate (PET) resin container), the generation of hydrolyzates of AFDX0250 can be suppressed. In addition, the inventors of the present application have found that by selecting a sterilization method (particularly filter filtration sterilization) for an aqueous pharmaceutical composition containing AFDX0250 or a salt thereof, the generation of hydrolyzates and similar substances derived from AFDX0250 in the aqueous pharmaceutical composition can be effectively suppressed. The present invention has been completed based on these findings.
[0018] Specifically, the present invention provides the following inventions.
[0019] [Item 1] A pharmaceutical preparation comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or a salt thereof is contained in a package that blocks light having a wavelength of 210 to 380 nm.
[0020] [Item 2] The pharmaceutical preparation according to Item 1, wherein the package has a light transmittance of light having a wavelength of 210 to 380 nm or an average value thereof of 20% or less.
[0021] [Item 3] The pharmaceutical preparation according to Item 1, wherein the package has a light transmittance of light having a wavelength of 210 to 380 nm or an average value thereof of 10% or less.
[0022] [Item 4] The pharmaceutical preparation according to any one of Items 1 to 3, wherein the package includes a primary package and a secondary package.
[0023] [Item 5] The pharmaceutical preparation according to Item 4, wherein the primary packaging body is a plastic container.
[0024] [Item 6] The pharmaceutical preparation according to Item 5, wherein the plastic container is a polyethylene resin container or a polyethylene terephthalate resin container.
[0025] [Item 7] The pharmaceutical preparation according to any one of Items 1 to 6, wherein the aqueous pharmaceutical composition is an aqueous pharmaceutical composition sterilized by filtration.
[0026] [Item 8] A pharmaceutical preparation comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or a salt thereof is contained in a plastic container.
[0027] [Item 9] The pharmaceutical preparation according to Item 8, wherein the plastic container is a polyethylene resin container or a polyethylene terephthalate resin container.
[0028] [Item 10] The pharmaceutical preparation according to Item 8 or Item 9, wherein the aqueous pharmaceutical composition is an aqueous pharmaceutical composition sterilized by filtration.
[0029] [Item 11] A pharmaceutical preparation comprising an aqueous pharmaceutical composition sterilized by filtration, wherein the aqueous pharmaceutical composition comprises (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof.
[0030] [Item 12] The pharmaceutical preparation according to any one of Items 1 to 11, which is an eye drop.
[0031] [Item 13] Reducing the amount of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition A method for stabilizing a -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of placing the aqueous pharmaceutical composition containing -6-ketone or a salt thereof in a package that blocks light having a wavelength of 210 to 380 nm.
[0032] [Item 14] Reducing the amount of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition A method for stabilizing a -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of storing the aqueous pharmaceutical composition containing -6-ketone or a salt thereof in a plastic container.
[0033] [Item 15] Reducing the amount of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition A method for stabilizing a -6-ketone or a salt thereof, comprising treating a mixture containing (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition containing β-6-ketone or a salt thereof is subjected to a filter filtration sterilization step.
[0034] [Item 16] Inhibition of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for photodecomposing a 6-ketone or a salt thereof, comprising: reacting a 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine containing (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl] A step of placing the aqueous pharmaceutical composition of -6-ketone or a salt thereof in a package that blocks light having a wavelength of 210 to 380 nm.
[0035] [Item 17] Improving the (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for thermal stability of -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of storing an aqueous pharmaceutical composition of -6-ketone or a salt thereof in a plastic container.
[0036] [Item 18] Inhibition of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in aqueous pharmaceutical compositions -6-ketone production method, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of storing the aqueous pharmaceutical composition containing -6-ketone or a salt thereof in a plastic container.
[0037] [Item 19] Inhibition of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in aqueous pharmaceutical compositions A method for producing an analog of -6-ketone or a salt thereof, comprising treating a compound containing (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition containing β-6-ketone or a salt thereof is subjected to a filter filtration sterilization step.
[0038] Two or more of the above-mentioned structures of [Item 1] to [Item 19] may be arbitrarily selected and combined.
[0039] Effects of the Invention
[0040] According to the present invention, the thermal stability and photostability of AFDX0250 or a salt thereof in an aqueous pharmaceutical composition can be improved. Therefore, it is not necessary to prepare a pharmaceutical composition containing AFDX0250 or a salt thereof as a non-aqueous preparation for stabilization.
[0041] In addition, in the pharmaceutical preparation of the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine Since the content of -6-ketone or its salt is stable, the preparation has excellent storage stability and safety, and can be used and stored for a long time. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] [ Figure 1 ] shows the absorption spectrum of AFDX0250 measured using a UV-visible spectrometer.
[0043] [ Figure 2 ] shows the content (residual rate (%)) of AFDX0250 in the test preparations (preparations 1 and 2) at each irradiation wavelength after 24 hours of irradiation.
[0044] [ Figure 3 ] shows the results of measuring the transmittance (%) of light at various wavelengths for various containers and secondary packages packaged in the containers. DETAILED DESCRIPTION
[0045] Hereinafter, the present invention will be described in detail.
[0046] The present invention provides a pharmaceutical preparation comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or a salt thereof is contained in a package that blocks light having a wavelength of 210 to 380 nm.
[0047] In the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The salt of -6-ketone is not particularly limited as long as it is a salt permitted as a medicine. Examples of its salt include salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, and phosphoric acid; salts formed with organic acids such as acetic acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, adipic acid, gluconic acid, glucoheptonic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, alanine, lactic acid, hippuric acid, 1,2-ethanedisulfonic acid, isethionic acid, lactobionic acid, oleic acid, gallic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl sulfuric acid, methyl sulfate, naphthalenesulfonic acid, and sulfosalicylic acid; salts formed with metals such as sodium, potassium, calcium, and magnesium; salts formed with inorganic compounds such as ammonia; and salts formed with organic amines such as triethylamine and guanidine.
[0048] In the present invention, the (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof may be in the form of a hydrate or a solvate.
[0049] In the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt can be prepared by a known method in the field of organic chemistry, and can also be obtained as a commercial product. For example, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone can be obtained by the process described in J. Med. Chem., 32(8), 1718-24, 1989.
[0050] In the present invention, the (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the aqueous pharmaceutical composition The content of -6-ketone or its salt is not particularly limited. The lower limit of the content is preferably 0.0001% (w / v), more preferably 0.0003% (w / v), further preferably 0.0005% (w / v), further more preferably 0.001% (w / v), particularly preferably 0.0013% (w / v), more particularly preferably 0.0015% (w / v), further particularly preferably 0.0017% (w / v), and most preferably 0.002% (w / v). The upper limit of the content is preferably 5% (w / v), more preferably 3% (w / v), further preferably 2% (w / v), further more preferably 1% (w / v), particularly preferably 0.5% (w / v), more particularly preferably 0.2% (w / v), and most preferably 0.1% (w / v). From preventing (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine From the viewpoint of precipitation of decomposition products of -6-ketone or its salt, the upper limit of the content is preferably 0.5% (w / v), more preferably 0.2% (w / v), and most preferably 0.1% (w / v). (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of -6-ketone or its salt is preferably 0.0001 to 5% (w / v), more preferably 0.0003 to 3% (w / v), further preferably 0.0005 to 2% (w / v), further more preferably 0.001 to 1% (w / v), particularly preferably 0.0013 to 0.5% (w / v), more particularly preferably 0.0015 to 0.2% (w / v), further particularly preferably 0.0017 to 0.1% (w / v), and most preferably 0.002 to 0.1% (w / v).
[0051] It should be noted that, in the present invention, "% (w / v)" refers to the mass (g) of the target component contained in 100 mL of the aqueous pharmaceutical composition of the present invention. In the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine In the case of a salt of -6-one, the value may be (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of the salt of -6-ketone may also be (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine In addition, in the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine When the -6-ketone or its salt is blended in the form of a hydrate or a solvate, the value may be (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of the hydrate or solvate of -6-ketone or its salt may also be (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine Unless otherwise specified, the following shall apply.
[0052] In the present invention, the so-called "aqueous pharmaceutical composition" refers to a pharmaceutical composition containing water. The content of water contained in the aqueous pharmaceutical composition of the present invention is not particularly limited, but is preferably 50% (w / v) or more, more preferably 70% (w / v) or more, and even more preferably 80% (w / v) or more relative to the aqueous pharmaceutical composition. It is particularly preferably 90% (w / v) or more, more preferably 95% (w / v) or more, and even more preferably 98% (w / v) or more.
[0053] In the present invention, the pH of the aqueous pharmaceutical composition is not particularly limited, and is, for example, 6.5 or less, preferably 4 to 6.5, more preferably 5 to 6.3, further preferably 5.3 to 6.2, and most preferably 5.5 to 6.
[0054] In the present invention, the aqueous pharmaceutical composition may contain, as long as it does not hinder the effects of the present invention, other than (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt, for example, an active ingredient showing therapeutic effect on eye diseases such as glaucoma, ocular hypertension, myopia, etc. In addition, the aqueous pharmaceutical composition may not contain any active ingredient other than (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salts, a pharmaceutically acceptable active ingredient. That is, it may contain (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt as the only active ingredient.
[0055] In the present invention, additives may be used in the aqueous pharmaceutical composition as needed. As additives, buffers, surfactants, isotonic agents, stabilizers, preservatives, antioxidants, high molecular weight polymers, pH adjusters, bases, etc. may be added.
[0056] In the present invention, a buffer that can be used as an additive for pharmaceuticals can be appropriately added to the aqueous pharmaceutical composition. Examples of the buffer include citric acid, acetic acid, malic acid, amines, amino acids, and salts thereof. In the present invention, the buffer preferably comprises citric acid or a salt thereof, and is further combined with any buffer selected from acetic acid or a salt thereof, malic acid or a salt thereof, amines or a salt thereof, or amino acids or a salt thereof.
[0057] Examples of the salt of citric acid include sodium citrate, disodium citrate, and trisodium citrate.
[0058] Examples of the salt of acetic acid include sodium acetate and potassium acetate.
[0059] Malic acid may be a racemate or an enantiomer (L-isomer or D-isomer). Examples of the salt of malic acid include sodium malate and disodium malate.
[0060] Examples of the amine include tromethamine, monoethanolamine, diethanolamine, triethanolamine, meglumine, etc. Examples of the salt of the amine include hydrochlorides and acetates thereof. In the present invention, the amine is preferably tromethamine, and examples of the salt thereof include tromethamine hydrochloride, etc.
[0061] As amino acids, for example, ε-aminocaproic acid, glycine, alanine, valine, leucine, serine, threonine, methionine, glutamine, glutamic acid, asparagine, aspartic acid, arginine, lysine, histidine, etc. can be mentioned, and when optical isomers exist, they can be racemates or enantiomers (L-body, D-body). As salts of amino acids, for example, their hydrochlorides, acetates, etc. can be mentioned. In the present invention, amino acids are preferably ε-aminocaproic acid, glycine, L-glutamine, and as salts thereof, glycine hydrochloride, L-glutamine hydrochloride, etc. can be mentioned.
[0062] In the present invention, the buffer may be in the form of a hydrate or a solvate, and examples thereof include citric acid hydrate and sodium citrate hydrate.
[0063] The lower limit of the content of the buffer in the aqueous pharmaceutical composition of the present invention is preferably 0.001% (w / v), more preferably 0.005% (w / v), further preferably 0.01% (w / v), further more preferably 0.05% (w / v), particularly preferably 0.1% (w / v), and most preferably 0.2% (w / v). The upper limit of the content of the buffer in the aqueous pharmaceutical composition of the present invention is, for example, 20% (w / v), preferably 10% (w / v), more preferably 5% (w / v), further preferably 4% (w / v), further more preferably 3% (w / v), particularly preferably 2% (w / v), and most preferably 1.5% (w / v). The content of the buffer in the aqueous pharmaceutical composition of the present invention is, for example, 0.001 to 20% (w / v), preferably 0.001 to 10% (w / v), more preferably 0.005 to 5% (w / v), further preferably 0.01 to 4% (w / v), further more preferably 0.05 to 3% (w / v), particularly preferably 0.1 to 2% (w / v), and most preferably 0.2 to 1.5% (w / v). For example, the content of the buffer in the aqueous pharmaceutical composition of the present invention can be 0.001% (w / v), 0.002% (w / v), 0.005% (w / v), 0.01% (w / v), 0.02% (w / v), 0.05% (w / v), 0.1% (w / v), 0.2% (w / v), 1.5% (w / v), 2% (w / v), 3% (w / v), 4% (w / v), 5% (w / v), 6% (w / v), 8% (w / v), 10% (w / v) or 20% (w / v).
[0064] In one embodiment of the pharmaceutical preparation of the present invention, the aqueous pharmaceutical composition preferably contains citric acid or a salt thereof and trometamol or a salt thereof as a buffer. In this case, the lower limits of the contents of citric acid or a salt thereof and trometamol or a salt thereof in the aqueous pharmaceutical composition are each preferably 0.0005% (w / v), more preferably 0.001% (w / v), further preferably 0.005% (w / v), further more preferably 0.01% (w / v), particularly preferably 0.05% (w / v), and most preferably 0.1% (w / v). The upper limits of their contents are each preferably 10% (w / v), more preferably 5% (w / v), further preferably 4% (w / v), further more preferably 3% (w / v), particularly preferably 2% (w / v), and most preferably 1.5% (w / v). In the present invention, the content of citric acid or its salt and tromethamine or its salt in the aqueous pharmaceutical composition is preferably 0.0005 to 10% (w / v), more preferably 0.001 to 5% (w / v), further preferably 0.005 to 4% (w / v), further more preferably 0.01 to 3% (w / v), particularly preferably 0.05 to 2% (w / v), and most preferably 0.1 to 1.5% (w / v).
[0065] In the present invention, a surfactant that can be used as an additive for pharmaceuticals, such as a cationic surfactant, an anionic surfactant, or a nonionic surfactant, can be appropriately blended into the aqueous pharmaceutical composition.
[0066] Examples of the anionic surfactant include phospholipids, and examples of the phospholipids include lecithin.
[0067] Examples of cationic surfactants include alkylamine salts, alkylamine polyoxyethylene adducts, fatty acid triethanolamine monoester salts, acylaminoethyldiethylamine salts, fatty acid polyamine condensates, alkyltrimethylammonium salts, dialkyldimethylammonium salts, alkyldimethylbenzylammonium salts, alkylpyridinium salts, acylaminoalkyl ammonium salts, acylaminoalkylpyridinium salts, diacyloxyethylammonium salts, alkylimidazolines, 1-acylaminoethyl-2-alkylimidazolines, 1-hydroxyethyl-2-alkylimidazolines, etc. Examples of alkyldimethylbenzylammonium salts include benzalkonium chloride and cetalkonium chloride.
[0068] Examples of the nonionic surfactant include polyoxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene polyoxypropylene glycol, sucrose fatty acid esters, and vitamin E TPGS.
[0069] Examples of the polyoxyethylene fatty acid ester include polyoxyl stearate 40 and the like.
[0070] Examples of the polyoxyethylene sorbitan fatty acid esters include polysorbate 80, polysorbate 65, polysorbate 60, polysorbate 40, polyoxyethylene sorbitan monolaurate, and polyoxyethylene sorbitan trioleate.
[0071] As the polyoxyethylene hydrogenated castor oil, various polyoxyethylene hydrogenated castor oils having different polymerization numbers of ethylene oxide can be used, and the polymerization number of ethylene oxide is preferably 10 to 100, more preferably 20 to 80, particularly preferably 40 to 70, and most preferably 60. Specific examples of the polyoxyethylene hydrogenated castor oil include polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, and the like.
[0072] As the polyoxyethylene castor oil, various polyoxyethylene castor oils having different polymerization numbers of ethylene oxide can be used, and the polymerization number of ethylene oxide is preferably 5 to 100, more preferably 20 to 50, particularly preferably 30 to 40, and most preferably 35. Specific examples of the polyoxyethylene castor oil include castor oil polyoxyl 5, castor oil polyoxyl 9, castor oil polyoxyl 15, castor oil polyoxyl 35, castor oil polyoxyl 40, and the like.
[0073] Examples of the polyoxyethylene polyoxypropylene diol include polyoxyethylene (160) polyoxypropylene (30) diol, polyoxyethylene (42) polyoxypropylene (67) diol, polyoxyethylene (54) polyoxypropylene (39) diol, polyoxyethylene (196) polyoxypropylene (67) diol, and polyoxyethylene (20) polyoxypropylene (20) diol.
[0074] Examples of the sucrose fatty acid ester include sucrose stearate and the like.
[0075] Vitamin E TPGS is also known as tocopheryl polyethylene glycol 1000 succinate.
[0076] When a surfactant is added to an aqueous pharmaceutical composition, the content of the surfactant can be appropriately adjusted depending on the type of the surfactant, etc., but is preferably 0.001 to 10% (w / v), more preferably 0.01 to 5% (w / v), further preferably 0.05 to 3% (w / v), and most preferably 0.1 to 2% (w / v).
[0077] In the present invention, an isotonic agent that can be used as an additive for pharmaceuticals can be appropriately added to the aqueous pharmaceutical composition to adjust the osmotic pressure. The osmotic pressure ratio of the aqueous pharmaceutical composition is, for example, 1, and there is no particular limitation as long as it is within the permissible range for pharmaceuticals. Examples of isotonic agents include ionic isotonic agents, nonionic isotonic agents, and the like.
[0078] Examples of the ionic isotonic agent include sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and the like, and examples of the nonionic isotonic agent include glycerin, propylene glycol, sorbitol, mannitol, and the like.
[0079] The content of the isotonic agent in the case of adding the isotonic agent to the aqueous pharmaceutical composition can be appropriately adjusted depending on the type of the isotonic agent, etc., but is preferably 0.01 to 10% (w / v), more preferably 0.02 to 7% (w / v), further preferably 0.1 to 5% (w / v), particularly preferably 0.3 to 4% (w / v), and most preferably 0.5 to 3% (w / v).
[0080] In the present invention, a stabilizer that can be used as an additive for pharmaceuticals can be appropriately blended into the aqueous pharmaceutical composition. Examples of the stabilizer include ethylenediaminetetraacetic acid, sodium ethylenediaminetetraacetate, and the like.
[0081] When a stabilizer is added to an aqueous pharmaceutical composition, the content of the stabilizer can be appropriately adjusted depending on the type of the stabilizer, etc., but is preferably 0.001 to 10% (w / v), more preferably 0.01 to 5% (w / v), further preferably 0.05 to 3% (w / v), and most preferably 0.1 to 2% (w / v).
[0082] In the present invention, a preservative that can be used as an additive for pharmaceuticals can be appropriately added to the aqueous pharmaceutical composition. Examples of preservatives include benzalkonium chloride, benzalkonium bromide, benzethonium chloride, sorbic acid, potassium sorbate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, chlorobutanol, and the like.
[0083] When a preservative is added to an aqueous pharmaceutical composition, the content of the preservative can be appropriately adjusted depending on the type of the preservative, etc., but is preferably 0.0001 to 1% (w / v), more preferably 0.0005 to 0.1% (w / v), further preferably 0.001 to 0.05% (w / v), and most preferably 0.002 to 0.01% (w / v).
[0084] In the present invention, an antioxidant that can be used as an additive for pharmaceuticals can be appropriately added to the aqueous pharmaceutical composition. Examples of antioxidants include tocophenol, butylated hydroxytoluene, butylated hydroxyanisole, sodium isoascorbate, propyl gallate, sodium sulfite, and the like.
[0085] When an antioxidant is added to an aqueous pharmaceutical composition, the content of the antioxidant can be appropriately adjusted depending on the type of the antioxidant, etc., but is preferably 0.0001 to 1% (w / v), more preferably 0.0005 to 0.1% (w / v), further preferably 0.001 to 0.02% (w / v), and most preferably 0.005 to 0.010% (w / v).
[0086] In the present invention, in the aqueous pharmaceutical composition, a high molecular weight polymer that can be used as an additive for pharmaceuticals can be appropriately matched. As examples of high molecular weight polymers, methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose (hydroxypropyl methylcellulose), carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, cellulose acetate phthalate, polyvinyl pyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, polyethylene glycol, etc. can be enumerated. In the present invention, the high molecular weight polymer is preferably hydroxypropyl methylcellulose (hydroxypropyl methylcellulose).
[0087] When a high molecular weight polymer is added to an aqueous pharmaceutical composition, the content of the high molecular weight polymer can be appropriately adjusted depending on the type of the high molecular weight polymer, etc., but is preferably 0.001 to 5% (w / v), more preferably 0.01 to 1% (w / v), and even more preferably 0.1 to 0.5% (w / v).
[0088] In the present invention, a pH adjuster that can be used as an additive for pharmaceuticals may be appropriately added to the aqueous pharmaceutical composition as long as the pH is 6.5 or less. Examples of the pH adjuster include hydrochloric acid, sodium hydroxide, potassium hydroxide, and the like.
[0089] When a pH adjuster is added to an aqueous pharmaceutical composition, the content of the pH adjuster can be appropriately adjusted depending on the type of the pH adjuster, etc., but is preferably 0.001 to 5% (w / v), more preferably 0.01 to 1% (w / v), and even more preferably 0.1 to 0.5% (w / v).
[0090] In the present invention, a base that can be used as an additive for pharmaceuticals can be appropriately blended into the aqueous pharmaceutical composition. Examples of the base include water, purified water, physiological saline, and the like.
[0091] In the present invention, the aqueous pharmaceutical composition can be administered orally or parenterally. Examples of administration routes include oral administration, intravenous administration, transdermal administration, topical administration to the eye (e.g., administration by eye drops, administration in the conjunctival sac, administration in the vitreous, administration under the conjunctiva, and administration under the Tenon's capsule).
[0092] The pharmaceutical preparation of the present invention is not particularly limited as long as it can be contained in the packaging body described below, and can be used in the form of preparations for eye diseases, such as eye drops, eye gels, injections, etc. The pharmaceutical preparation of the present invention is particularly preferably used in the form of eye drops.
[0093] These dosage forms can be produced according to conventional methods in the art.
[0094] The pharmaceutical preparation of the present invention can be provided by storing the aqueous pharmaceutical composition in a package that blocks light in a specific wavelength range. The package can be any package that can block light in a specific wavelength range under the storage state generally envisioned for pharmaceutical preparations, and its airtightness is not particularly limited. In addition, as for the means for storing the aqueous pharmaceutical composition in the package, it can be filled by a conventional method according to the form of the package.
[0095] In the present invention, the so-called "package" refers to an object that directly or indirectly contains the aqueous pharmaceutical composition of the present invention. Among the packages, the package that directly contains the aqueous pharmaceutical composition of the present invention is called a "primary package", and the package that indirectly contains the aqueous pharmaceutical composition of the present invention is called a "secondary package".
[0096] Examples of primary packaging bodies include eye drop containers, injection containers, tubular containers, bottle containers, spray containers, etc., and examples of secondary packaging bodies include medicine bags, aluminum pillows, boxes, shrinks, paper labels, etc. Primary packaging bodies and secondary packaging bodies do not include aluminum packaging bodies such as aluminum foil.
[0097] In the present invention, the wavelength range of the light blocked by the packaging body is 210-380nm, preferably 215-340nm and 350-380nm, more preferably 216nm-310nm and 370-380nm, and most preferably 216, 247, 278, 310 or 372nm.
[0098] In the present invention, the so-called "blocking light in the aforementioned wavelength range" means: the transmittance of the light in the wavelength range is 50% or less, or the light shielding rate is greater than 50%, or the average value of the transmittance of the light in the wavelength range is 50% or less, or the average value of the light shielding rate is greater than 50%. For example, the so-called "package that blocks light with a wavelength of 210 to 380nm" refers to a package whose transmittance of light with a wavelength of 210 to 380nm or the average value of the transmittance of light with a wavelength of 210 to 380nm is 50% or less. In the present invention, from the viewpoint of further improving stability against light, the transmittance of light with a wavelength of 210 to 380nm or its average value is preferably 30% or less, more preferably 20% or less, further preferably 15% or less, particularly preferably 10% or less, and most preferably 5% or less.
[0099] It should be noted that, in the present invention, as for the method for measuring the transmittance, the transmittance of the wavelength of 210 to 800 nm can be measured and calculated using an ultraviolet visible spectrometer. It should be noted that it is not necessary for the entire package to block the light in the aforementioned wavelength range, but it is preferred that more than 50% of the total area of the inner surface of the package block the light in the aforementioned wavelength range, more preferably more than 60% of the area blocks the light in the aforementioned wavelength range, further preferably more than 70% of the area blocks the light in the aforementioned wavelength range, further more preferably more than 80% of the area blocks the light in the aforementioned wavelength range, particularly preferably more than 90% of the area blocks the light in the aforementioned wavelength range, more particularly preferably more than 95% of the area blocks the light in the aforementioned wavelength range, and most preferably 100% of the area blocks the light in the aforementioned wavelength range. As a method for blocking the light in the aforementioned wavelength range in part of the total area of the inner surface of the package, for example, it is preferred that a secondary package (shrinking body, paper label, etc.) that blocks the light in the aforementioned wavelength range is wound around the side of a primary package (eye drop container, etc.) that does not block the light in the aforementioned wavelength range.
[0100] When the pharmaceutical preparation of the present invention includes a secondary package, it is sufficient that either the primary package or the secondary package blocks the light in the aforementioned wavelength range. In addition, even if the primary package and the secondary package alone cannot block the light in the aforementioned wavelength range, as long as the light in the aforementioned wavelength range can be blocked as a result of combining the primary package and the secondary package, in this case, there may be a plurality of secondary packages. With respect to the pharmaceutical preparation of the present invention, it is desirable that the primary package blocks the light in a specific wavelength range from the viewpoint of suppressing the decomposition of AFDX0250 or its salt not only during circulation and storage but also during use.
[0101] In the present invention, the material of the package is not particularly limited, and examples thereof include plastic, cellulose, pulp, rubber, and metal.
[0102] As a primary package for directly storing an aqueous pharmaceutical composition, a plastic container is preferred. From the viewpoint of further stabilizing AFDX0250 or its salt, a polyethylene resin container, a polypropylene container, and a polyethylene terephthalate resin container are more preferred. From the viewpoint of stabilizing AFDX0250 or its salt for a longer period of time, a polyethylene resin container and a polyethylene terephthalate resin container are most preferred. In addition, from the viewpoint of internal visibility, a primary package is preferably a transparent container. In the case of a transparent container, it is transparent to the extent that the interior can be viewed. The so-called transparent to the extent that it can be viewed is that the transmittance of visible light (wavelength of about 400nm to about 800nm) or its average value is, for example, 20% or more, preferably 30% or more, more preferably 40% or more, further preferably 50% or more, further more preferably 60% or more, particularly preferably 70% or more, more particularly preferably 80% or more, and most preferably 90% or more. The entire container does not need to be transparent to the extent that the inside can be seen, but preferably 30% or more of the total area of the outer surface of the container is transparent, more preferably 50% or more, further preferably 70% or more, further more preferably 80% or more, particularly preferably 90% or more, and most preferably 95% or more. In addition, the primary package may not be a transparent container.
[0103] As the material of the secondary package for indirectly storing the aqueous pharmaceutical composition, plastic, cellulose, pulp, paper, etc. are preferably used from the viewpoint of processability. In addition, the secondary package may be opaque, but from the viewpoint of internal visibility, the secondary package may be transparent. When the secondary package is transparent, it is sufficient to be transparent to the extent that the inside can be viewed. The so-called transparent to the extent that it can be viewed is, for example, a transmittance of visible light (wavelength of about 400nm to about 800nm) or its average value of 20% or more, preferably 30% or more, more preferably 40% or more, further preferably 50% or more, further more preferably 60% or more, particularly preferably 70% or more, more particularly preferably 80% or more, and most preferably 90% or more. The entire secondary packaging body need not be transparent to the extent that the interior can be viewed, but preferably 1% or more of the total area of the outer surface of the secondary packaging body is transparent, preferably 5% or more of the area is transparent, more preferably 10% or more of the area is transparent, further preferably 30% or more of the area is transparent, further more preferably 50% or more of the area is transparent, particularly preferably 90% or more of the area is transparent, and most preferably 95% or more of the area is transparent. In addition, the secondary packaging body may not be a transparent container, but may be a packaging body with a transparent slit (viewing window) for viewing the interior.
[0104] In the present invention, the so-called "polyethylene (PE) resin container" (hereinafter, sometimes referred to as "PE container") refers to a container in which at least the portion of the container that contacts the aqueous pharmaceutical composition is a polyethylene resin. Examples of polyethylene include low-density polyethylene (LDPE), medium-density polyethylene (MDPE), and high-density polyethylene (HDPE). In addition, the so-called "polypropylene (PP) resin container" (hereinafter, sometimes referred to as "PP container") refers to a container in which at least the portion of the container that contacts the aqueous pharmaceutical composition is a polypropylene resin. The so-called "polyethylene terephthalate (PET) resin container" (hereinafter, sometimes referred to as "PET container") refers to a container in which at least the portion of the container that contacts the aqueous pharmaceutical composition is a polyethylene terephthalate resin.
[0105] In addition, the pharmaceutical preparation of the present invention preferably comprises a sterilized aqueous pharmaceutical composition. Examples of sterilization methods for aqueous pharmaceutical compositions include electron beam (EB) sterilization, ethylene oxide gas (EOG) sterilization, hydrogen peroxide sterilization, gamma ray sterilization, filter filtration sterilization, and high pressure steam (AC) sterilization. In the pharmaceutical preparation of the present invention, filter filtration sterilization is particularly preferred as a sterilization method for aqueous pharmaceutical compositions.
[0106] In the present invention, the so-called "electron beam sterilization" or "EB sterilization" is a sterilization method that can kill bacteria and the like using an electron beam, and there is no particular limitation as long as it is a method for sterilizing using an electron beam. For example, if it is an irradiation dose, it can be appropriately selected between 1 and 100 kGy, and if it is an irradiation time, it can be appropriately selected between several seconds and several minutes.
[0107] In the present invention, the so-called "ethylene oxide gas sterilization" or "EOG sterilization" is a sterilization method that can kill bacteria and the like using ethylene oxide gas, and there is no particular limitation as long as it is a method for sterilization using ethylene oxide gas. For example, the sterilization temperature can be 30 to 60°C, the sterilization time can be 1 to 10 hours, and the gas used can be only ethylene oxide gas, or a mixed gas of ethylene oxide gas and carbon dioxide, etc., which can be appropriately selected.
[0108] In the present invention, "hydrogen peroxide sterilization" refers to a sterilization method that can kill bacteria and the like using hydrogen peroxide, and the method is not particularly limited as long as it is a method for sterilization using hydrogen peroxide.
[0109] In the present invention, "gamma ray sterilization" refers to a sterilization method that can kill bacteria and the like using gamma rays, and the method is not particularly limited as long as it is a method for performing a sterilization treatment using gamma rays.
[0110] In the present invention, the so-called "filter sterilization" is a sterilization method for removing bacteria and the like by filtering using a membrane filter with a pore size of 0.22 μm. The membrane filter can use filters made of materials such as PVDF (polyvinylidene fluoride), PES (polyethersulfone), PTFE (polytetrafluoroethylene), and MCE (cellulose mixed ester). In addition, filters with different pore sizes can also be used, such as filters with a pore size of 0.1 to 0.3 μm, a pore size of 0.2 to 0.25 μm, a pore size of 0.2 μm, a pore size of 0.21 μm, a pore size of 0.23 μm, a pore size of 0.24 μm, and a pore size of 0.25 μm.
[0111] In the present invention, the so-called "high pressure steam (AC) sterilization" is a sterilization method that can kill bacteria and the like using a high pressure steam sterilizer (autoclave), and there is no particular limitation as long as it is a method for sterilization using a high pressure steam sterilizer (autoclave). For example, it is preferably carried out at 115-118°C for 30 minutes, 121-124°C for 15-20 minutes, or 126-129°C for 10 minutes, and is carried out until the object reaches a sterile state.
[0112] When the pharmaceutical preparation of the present invention is used as an eye drop, the eye drop container may be a container consisting of one component or a container consisting of multiple components. In the present invention, the aqueous pharmaceutical composition may be contained in any container such as a one-piece eye drop container consisting of one component, a two-piece eye drop container consisting of two components, or a three-piece eye drop container consisting of three components. For example, a three-piece eye drop container is formed by three components, namely, a container body for storing an aqueous pharmaceutical composition, an inner plug, and a lid. In addition, an integrally molded container that is blow molded and filled with a liquid medicine at the same time is also included in the aforementioned eye drop container according to the number of its components. When the container is formed of multiple components, it can be formed by components of the same material or by components of different materials.
[0113] When the pharmaceutical preparation of the present invention is used as an eye drop, it can be contained in any of a multi-dose container, a single-dose container, or a PFMD (Preservative Free Multi Dose) container.
[0114] The pharmaceutical preparation of the present invention can be used for the treatment of eye diseases such as glaucoma, ocular hypertension, myopia, etc.
[0115] The present invention provides a pharmaceutical preparation comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The above detailed description of the present invention is also applicable to the following pharmaceutical preparation, which contains (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or a salt thereof is contained in a plastic resin container.
[0116] In the present invention, the aqueous pharmaceutical composition is contained in a plastic container. From the viewpoint of further stabilizing AFDX 0250 or a salt thereof, it is preferably contained in a polyethylene resin container, a polypropylene resin container, or a polyethylene terephthalate resin container. From the viewpoint of stabilizing AFDX 0250 or a salt thereof for a longer period of time, it is most preferably contained in a polyethylene resin container or a polyethylene terephthalate resin container. By containing the aqueous pharmaceutical composition in a plastic container, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the aqueous pharmaceutical composition can be particularly stabilized compared to other containers. -6-ketone or its salt is stabilized.
[0117] The present invention provides a pharmaceutical preparation, which comprises an aqueous pharmaceutical composition sterilized by filtration through a filter, wherein the aqueous pharmaceutical composition comprises (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The above detailed description of the present invention also applies to the following pharmaceutical preparation, the pharmaceutical preparation comprising an aqueous pharmaceutical composition sterilized by filtration, the aqueous pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof.
[0118] In the present invention, the aqueous pharmaceutical composition is a sterilized aqueous pharmaceutical composition by filtration. By performing sterilization by filtration, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the aqueous pharmaceutical composition can be particularly reduced compared to other sterilization methods. -6-ketone or its salt is stabilized.
[0119] The present invention provides a method for making (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition. The above detailed description of the present invention is also applicable to stabilizing (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition. -6-ketone or its salt stabilization method.
[0120] In the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the aqueous pharmaceutical composition The method for stabilizing -6-ketone or its salt comprises the following method, wherein the method comprises: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or its salt is contained in a package that blocks light of wavelength 210 to 380 nm. According to this method, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine can be inhibited. -6-ketone or its salt decomposes under light irradiation, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The -6-ketone or its salt becomes stable with respect to light.
[0121] In the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the aqueous pharmaceutical composition The method for stabilizing -6-ketone or a salt thereof comprises the following method, wherein the method comprises (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or its salt is contained in a plastic container. From the viewpoint of further stabilizing AFDX0250 or its salt, it is preferably contained in a polyethylene resin container, a polypropylene resin container or a polyethylene terephthalate resin container. From the viewpoint of stabilizing AFDX0250 or its salt for a longer period of time, it is most preferably contained in a polyethylene resin container and a polyethylene terephthalate resin container. According to this method, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine can be inhibited. The hydrolysis of -6-ketone can inhibit the hydrolysis of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine In addition, according to this method, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt becomes stable with respect to heat.
[0122] In the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the aqueous pharmaceutical composition The method for stabilizing -6-ketone or a salt thereof comprises the following steps: The aqueous pharmaceutical composition of -6-ketone or its salt is sterilized by filtration. This method can effectively inhibit the hydrolyzate in the aqueous pharmaceutical composition and the (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone analogs.
[0123] Example
[0124] Examples are shown below, but these are for better understanding of the present invention and do not limit the scope of the present invention.
[0125] Preparation Examples
[0126] Representative formulation examples of the present invention are shown below. In addition, the blending amount (% (w / v)) of each component in the following formulation examples is the content (g) in 100 mL of the composition.
[0127] [Preparation Example 1]
[0128] Eye drops (100mL)
[0129]
[0130] Sterilization method: Filter sterilization
[0131] Container: Polyethylene resin container (light transmittance of 210 to 380 nm wavelength is less than 10%)
[0132] [Preparation Example 2]
[0133] Eye drops (100mL)
[0134]
[0135] Sterilization method: Filter sterilization
[0136] Container: Polyethylene terephthalate resin container (light transmittance of 210 to 380 nm wavelength is less than 10%)
[0137] [Preparation Example 3]
[0138] Eye drops (100mL)
[0139]
[0140] Sterilization method: Filter sterilization
[0141] Container: Polyethylene resin container (light transmittance of 210 to 380 nm wavelength is less than 10%)
[0142] It should be noted that the types and amounts of AFDX0250, buffers, and additives in the above-mentioned Preparation Examples 1 to 3 can be appropriately adjusted to obtain a desired composition.
[0143] Example 1: Thermal stability test (1)
[0144] The thermal stability of AFDX0250 in pharmaceutical preparations was evaluated by confirming the amount of hydrolyzate of AFDX0250 produced as a by-product after storage under certain conditions.
[0145] (1) Test preparation
[0146] An aqueous pharmaceutical composition (preparation 1) having a formulation shown in Table 1 was prepared by a conventional method, and the composition was filled into a PE container, a PP container, a PET container, and a glass container to prepare a test preparation.
[0147] [Table 1]
[0148] Preparation 1 AFDX0250 0.50% Sodium chloride 0.68% Sodium hydroxide Moderate Dilute hydrochloric acid Moderate Water for injection Moderate p H 6
[0149] (2) Test methods
[0150] The prepared test preparations were stored at 25°C for 1 month. 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine produced by hydrolysis of AFDX0250 in each test preparation after 1 month of storage was analyzed by high performance liquid chromatography. The content of -6-ketone (hereinafter sometimes referred to as "hydrolyzate") was quantified and its generation rate (%) was calculated. It should be noted that the generation rate (%) is the ratio (%) when the mass of AFDX0250 contained in the test preparation is set to 100%.
[0151] (3) Results
[0152] Table 2 shows the production rate (%) of the hydrolyzate of AFDX0250 in each test preparation.
[0153] [Table 2]
[0154]
[0155] As shown in the test results, the aqueous pharmaceutical composition containing AFDX0250 or a salt thereof can suppress the generation rate of hydrolyzates to a lower level by storing it in a plastic container compared to a glass container. As a result, it was confirmed that AFDX0250 has excellent stability in the aqueous pharmaceutical composition by storing it in a plastic container.
[0156] Example 2: Thermal stability test (2)
[0157] The thermal stability of AFDX0250 in the pharmaceutical preparation was evaluated by visually confirming the precipitate in the test preparation after storage under certain conditions.
[0158] (1) Test preparation
[0159] Preparation 1 prepared in Example 1 was filled into a PE container, a PET container, a PP container, and a glass container to prepare a test preparation.
[0160] (2) Test methods
[0161] The prepared test preparation was stored at 40° C. for 2 weeks. The presence or absence of precipitates in the test preparation after storage was visually confirmed.
[0162] (3) Results
[0163] The test results are shown in Table 3. "-" in the table means that no precipitate was generated.
[0164] [Table 3]
[0165]
[0166] As shown in the test results, when the aqueous pharmaceutical composition containing AFDX0250 or a salt thereof was stored in a glass container, the generation of precipitates was observed after 2 weeks, but when it was stored in a plastic container, the generation of precipitates was not observed. As a result, it was confirmed that AFDX0250 has excellent storage stability in the aqueous pharmaceutical composition by being stored in a plastic container.
[0167] Example 3: Absorption wavelength measurement test
[0168] The absorption wavelength of AFDX0250 was measured.
[0169] (1) Test preparation
[0170] AFDX0250 (10 mg) was dissolved in acetonitrile and the volume was accurately adjusted to 100 mL to prepare a 0.01% AFDX0250 solution. This solution was diluted 4-fold to prepare a 0.0025% AFDX0250 solution as a test preparation.
[0171] (2) Test methods
[0172] The absorption spectrum of the prepared test preparation was measured using a UV-visible spectrometer.
[0173] (3) Results
[0174] The test results are shown in Figure 1 .
[0175] As shown in the present test results, absorption of AFDX0250 is not observed at wavelengths longer than about 330 nm.
[0176] Example 4: Photostability test (1)
[0177] The stability of aqueous pharmaceutical compositions comprising AFDX0250 or a salt thereof with respect to light irradiation was studied.
[0178] (1) Test preparation
[0179] Preparation 1 of the formulation shown in Table 1 and Preparation 2 of the formulation shown in Table 4 were prepared by conventional methods as test preparations.
[0180] [Table 4]
[0181] Preparation 2 AFDX 0250 0.50% Sodium Citrate Hydrate 0.15% Tromethamine 0.10% Sodium chloride 0.68% Sodium hydroxide Moderate Dilute hydrochloric acid Moderate Water for injection Moderate p H 6
[0182] (2) Test methods
[0183] The prepared test preparation was irradiated with a specific wavelength for 24 hours using a multi-wavelength irradiation spectrometer, and the content of AFDX0250 in the test preparation at each irradiation wavelength after irradiation was quantified using high performance liquid chromatography to calculate its residual rate (%). It should be noted that the residual rate (%) is the ratio (%) when the mass of AFDX0250 contained in the test preparation is set to 100%.
[0184] (3) Results
[0185] The test results are shown in Figure 2 .
[0186] As shown in the test results, AFDX0250 was decomposed at wavelengths of 216 to 310 nm and 372 nm. In particular, decomposition of AFDX0250 was also observed at 370 nm, which is not the absorption wavelength of AFDX0250. As a result, it can be seen that although AFDX is unstable to light, it is limited to these specific wavelengths, suggesting that by blocking light in the wavelength range including these wavelengths, the photostability of AFDX0250 in the aqueous pharmaceutical composition can be ensured.
[0187] Example 5: Light stability test (2)
[0188] The stability of a pharmaceutical preparation obtained by packaging an aqueous pharmaceutical composition containing AFDX0250 or a salt thereof with respect to light irradiation was studied.
[0189] (1) Test preparation
[0190] Preparation 2 prepared in Example 4 was filled into a glass container, an eye drop container (A), an eye drop container (A) packaged in a shrink body, an eye drop container (A) packaged in a paper label, an eye drop container (A) packaged in a box, an eye drop container (A) packaged in a medicine bag (A), a medicine bag (B), a medicine bag (C), and a medicine bag (D), an eye drop container (A) packaged in an aluminum pillow, an eye drop container (B), an eye drop container (C), and an eye drop container (D), thereby preparing a test preparation.
[0191] (2) Test methods
[0192] The content of AFDX0250 when the prepared test preparation was exposed to 1.2 million lux·hr or more was quantified using high performance liquid chromatography, and the residual rate (%) was calculated. It should be noted that the residual rate (%) is the ratio (%) when the mass of AFDX0250 contained in the test preparation is set to 100%.
[0193] In addition, the light transmittance of various containers and secondary packages packaged in the containers at various wavelengths was measured.
[0194] (3) Results
[0195] The residual rate (%) of AFDX0250 in each package is shown in Table 5. In addition, the results of measuring the light transmittance of various containers and secondary packages packaged in the containers at various wavelengths are shown in Table 5. Figure 3 The wavelengths at which the light transmittance of various containers and secondary packages packaged in the containers is 10% or less, 20% or less, 30% or less, and 50% or less are shown in Table 6. In addition, the light transmittance of various containers at a wavelength of 370 nm is shown in Table 7.
[0196] [Table 5]
[0197]
[0198] [Table 6]
[0199]
[0200] [Table 7]
[0201]
[0202] The test results confirmed that the photodecomposition of AFDX0250 can be suppressed by storing an aqueous pharmaceutical composition containing AFDX0250 or a salt thereof in a package whose transmittance of light at wavelengths of 216 to 310 nm and 372 nm is suppressed to 50% or less. The results show that the photostability of AFDX0250 in an aqueous pharmaceutical composition can be ensured by using a package whose transmittance of light in a wavelength range including these specific wavelengths is suppressed to 50% or less.
[0203] Example 6: Stability Evaluation Test
[0204] An aqueous pharmaceutical composition containing AFDX0250 or a salt thereof was sterilized, and the stability of AFDX0250 in the formulation was studied.
[0205] (1) Test preparation
[0206] Dissolve 2.5 g of sodium citrate hydrate in purified water and accurately adjust the volume to 100 mL to prepare a 2.5% sodium citrate hydrate solution. Dissolve 0.2 g of citric acid hydrate in purified water and accurately adjust the volume to 100 mL to prepare a 0.2% citric acid hydrate solution. Dissolve 5 g of sodium chloride in purified water and accurately adjust the volume to 50 mL to prepare a 10% sodium chloride solution. Measure 0.25 g of AFDX0250, measure 10 mL of each of 2.5% sodium citrate hydrate solution, 0.2% citric acid hydrate solution, and 10% sodium chloride solution, and add them thereto, use purified water to accurately adjust the volume to 50 mL to prepare the test preparation.
[0207] (2) Test methods
[0208] The prepared test preparation is subjected to gamma ray sterilization, filter filtration sterilization or high-pressure steam (AC) sterilization to prepare a sterile preparation. The content of AFDX0250 after sterilization is quantified using high performance liquid chromatography, and its residual rate (%) is calculated. It should be noted that the residual rate (%) is the ratio when the mass of AFDX0250 contained in the test preparation is set to 100%. In addition, in addition to the test preparation subjected to gamma ray sterilization, the hydrolyzate from AFDX0250 (5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone) was quantified.
[0209] (3) Results
[0210] Table 8 shows the residual rate (%) of AFDX0250 and the content (%) of the hydrolyzate in the test preparations subjected to each sterilization treatment.
[0211] [Table 8]
[0212] Gamma irradiation sterilization Filter sterilization AC Sterilization Residual rate (%) 55.7 100.3 93.8 Hydrolyzate (%) - 0.06 0.37
[0213] The test results show that the reduction in the residual rate of AFDX0250 and the generation of hydrolyzates are effectively suppressed in the preparations subjected to filter sterilization. This result shows that the pharmaceutical preparations of the present invention can maintain higher storage stability by performing filter sterilization.
[0214] Industrial Applicability
[0215] According to the present invention, the thermal stability and photostability of AFDX0250 or a salt thereof in an aqueous pharmaceutical composition can be improved, and thus a pharmaceutical preparation having excellent stability can be provided.
Claims
1. A pharmaceutical preparation comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or a salt thereof is contained in a package that blocks light having a wavelength of 210 to 380 nm.
2. The pharmaceutical preparation according to claim 1, wherein The package body has a light transmittance of light having a wavelength of 210 to 380 nm or an average value thereof of 20% or less.
3. The pharmaceutical preparation according to claim 1, wherein The package has a light transmittance of light having a wavelength of 210 to 380 nm or less or an average value thereof of 10% or less.
4. The pharmaceutical preparation according to any one of claims 1 to 3, wherein The packaging body includes a primary packaging body and a secondary packaging body.
5. The pharmaceutical preparation according to claim 4, wherein The primary packaging body is a plastic container.
6. The pharmaceutical preparation according to claim 5, wherein The plastic container is a polyethylene resin container, a polypropylene resin container or a polyethylene terephthalate resin container.
7. The pharmaceutical preparation according to any one of claims 1 to 6, wherein The aqueous pharmaceutical composition is an aqueous pharmaceutical composition that has been sterilized by filtration.
8. A pharmaceutical preparation comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition of -6-ketone or a salt thereof is contained in a plastic container.
9. The pharmaceutical preparation according to claim 8, wherein The plastic container is a polyethylene resin container, a polypropylene resin container or a polyethylene terephthalate resin container.
10. The pharmaceutical preparation according to claim 8 or 9, wherein The aqueous pharmaceutical composition is an aqueous pharmaceutical composition that has been sterilized by filtration.
11. A pharmaceutical preparation comprising an aqueous pharmaceutical composition sterilized by filtration, wherein the aqueous pharmaceutical composition comprises (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof. 12 . The pharmaceutical preparation according to claim 1 , which is an eye drop.
13. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition A method for stabilizing a -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of placing the aqueous pharmaceutical composition containing -6-ketone or a salt thereof in a package that blocks light having a wavelength of 210 to 380 nm.
14. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition A method for stabilizing a -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The step of storing the aqueous pharmaceutical composition containing -6-ketone or a salt thereof in a plastic container.
15. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an aqueous pharmaceutical composition A method for stabilizing a -6-ketone or a salt thereof, comprising treating a mixture containing (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The aqueous pharmaceutical composition containing β-6-ketone or a salt thereof is subjected to a filter filtration sterilization step.
